Clinical trial

Efficacy of Digital Sedation Compared With Neuroleptanalgesia in Percutaneous Outpatient Surgery for Superficial Venous Insufficiency

Name
2023-A01948-37
Description
Virtual reality has been shown to reduce the pain experienced during medical procedures. The aim of this study is to determine to what extent the use of this technique could make it possible to defer the administration of neuroleptanalgesia during the endovenous thermal treatment of superficial varicose veins in addition to local anaesthesia by tumescence.
Trial arms
Trial start
2023-11-20
Estimated PCD
2024-12-01
Trial end
2024-12-01
Status
Recruiting
Treatment
use of a device incorporating virtual reality software
use of a device incorporating virtual reality software
Arms:
use of a device incorporating virtual reality software
Neuroleptanalgesia
Usual neuroleptanalgesic treatment
Arms:
usual neuroleptanalgesic treatment
Size
400
Primary endpoint
Pain intensity assessed by NRS (numerical rating scale)
Day 1
Eligibility criteria
Inclusion Criteria: * Patient aged 18 or over, who has read and signed the consent form for participation in the study after a reflection period (approximately 1 hour). * Outpatients with superficial venous insufficiency for which a surgical indication has been given * Patient requiring sedation associated with local anesthesia Exclusion Criteria: * Contraindication to local anesthesia or any of the sedatives used in the protocol * Hearing or visual impairment contraindicating use of the virtual reality headset * Pregnant or breast-feeding patients * Unbalanced epilepsy * Patients under court protection, guardianship or curatorship * Patients not affiliated to the French social security system * Patient unable to understand informed information and/or give written informed consent: dementia, psychosis, disturbed consciousness, non-French-speaking patient
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Prospective, randomised, open-label, single-centre study in two parallel groups of 200 patients.\n\nMaximum duration of patient participation in the study = 2 days.', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 400, 'type': 'ESTIMATED'}}
Updated at
2024-01-29

1 organization

1 product

1 indication